| 1 |
34158343 | The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells. | 2021 Sep |
3 |
| 2 |
31801023 | Targeting c-Src Reverses Accelerated GPX-1 mRNA Decay in Chronic Obstructive Pulmonary Disease Airway Epithelial Cells. | 2020 May |
1 |
| 3 |
32346533 | Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis. | 2020 |
1 |
| 4 |
32372484 | The dual role of c-src in cell-to-cell transmission of α-synuclein. | 2020 Jul 3 |
1 |
| 5 |
32604782 | Redox Regulation of NOX Isoforms on FAK(Y397)/SRC(Y416) Phosphorylation Driven Epithelial-to-Mesenchymal Transition in Malignant Cervical Epithelial Cells. | 2020 Jun 26 |
1 |
| 6 |
30207834 | TLK2 enhances aggressive phenotypes of glioblastoma cells through the activation of SRC signaling pathway. | 2019 |
1 |
| 7 |
30628679 | CX3CL1 promotes lung cancer cell migration and invasion via the Src/focal adhesion kinase signaling pathway. | 2019 Mar |
1 |
| 8 |
31416844 | Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma. | 2019 Oct 1 |
1 |
| 9 |
31667062 | An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. | 2019 Dec |
2 |
| 10 |
31805962 | Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma. | 2019 Dec 5 |
5 |
| 11 |
29401603 | Hepatitis B virus core protein promotes hepatocarcinogenesis by enhancing Src expression and activating the Src/PI3K/Akt pathway. | 2018 Jun |
1 |
| 12 |
29435137 | Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. | 2018 Jan 12 |
3 |
| 13 |
29550144 | miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway. | 2018 May 1 |
1 |
| 14 |
29601121 | PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells. | 2018 Jun |
2 |
| 15 |
29959144 | Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells. | 2018 Oct 1 |
1 |
| 16 |
30166523 | CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair. | 2018 Aug 30 |
1 |
| 17 |
28049762 | The tyrosine kinase Src promotes phosphorylation of the kinase TBK1 to facilitate type I interferon production after viral infection. | 2017 Jan 3 |
1 |
| 18 |
28116540 | GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells. | 2017 Apr |
1 |
| 19 |
28396832 | AZD0530 sensitizes drug-resistant ALK-positive lung cancer cells by inhibiting SRC signaling. | 2017 Apr |
2 |
| 20 |
28455521 | Importance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts. | 2017 Apr 28 |
1 |
| 21 |
29021139 | Paxillin Binding to the Cytoplasmic Domain of CD103 Promotes Cell Adhesion and Effector Functions for CD8+ Resident Memory T Cells in Tumors. | 2017 Dec 15 |
1 |
| 22 |
27460949 | Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma. | 2016 Sep |
2 |
| 23 |
27475932 | Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib. | 2016 Oct 10 |
1 |
| 24 |
27666484 | Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer. | 2016 Oct 21 |
2 |
| 25 |
27766744 | PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines. | 2016 Dec |
1 |
| 26 |
28036386 | Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway. | 2016 |
2 |
| 27 |
25338626 | Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells. | 2015 Jan |
1 |
| 28 |
25662515 | Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. | 2015 Apr |
1 |
| 29 |
25820822 | Aflatoxin B1 induces Src phosphorylation and stimulates lung cancer cell migration. | 2015 Aug |
1 |
| 30 |
26009269 | A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. | 2015 Jul |
3 |
| 31 |
26045172 | ATF6 pathway of unfolded protein response mediates advanced oxidation protein product-induced hypertrophy and epithelial-to-mesenchymal transition in HK-2 cells. | 2015 Sep |
2 |
| 32 |
26062928 | Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. | 2015 Aug |
3 |
| 33 |
26170970 | The importance of Src signaling in sarcoma. | 2015 Jul |
1 |
| 34 |
26208525 | Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma. | 2015 Oct |
1 |
| 35 |
26474384 | Identification of drugs as single agents or in combination to prevent carcinoma dissemination in a microfluidic 3D environment. | 2015 Nov 3 |
1 |
| 36 |
24111605 | Cigarette smoke activates the proto-oncogene c-src to promote airway inflammation and lung tissue destruction. | 2014 Mar |
1 |
| 37 |
24169259 | A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. | 2014 Jan |
2 |
| 38 |
24200972 | Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib. | 2014 |
1 |
| 39 |
24492292 | The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer. | 2014 Mar-Apr |
2 |
| 40 |
24495408 | Fyn kinase inhibition as a novel therapy for Alzheimer's disease. | 2014 |
2 |
| 41 |
24612061 | Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors. | 2014 May |
1 |
| 42 |
24828915 | Fluorescent visualization of Src by using dasatinib-BODIPY. | 2014 Jun 16 |
2 |
| 43 |
24887236 | Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. | 2014 May 5 |
1 |
| 44 |
24968896 | An ovarian cancer model with positive ER: Reversion of ER antagonist resistance by Src blockade. | 2014 Sep |
1 |
| 45 |
25070546 | A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†. | 2014 Oct |
2 |
| 46 |
25108485 | Dysregulated activation of c-Src in gestational trophoblastic disease contributes to its aggressive progression. | 2014 Oct |
2 |
| 47 |
25114223 | Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. | 2014 Aug 26 |
1 |
| 48 |
25226534 | SP600125 induces Src and type I IGF receptor phosphorylation independent of JNK. | 2014 Sep 15 |
1 |
| 49 |
22310287 | Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. | 2013 Jan 3 |
5 |
| 50 |
22415795 | First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours. | 2013 Feb |
4 |